1. All Stories
  2. Politics
  3. Economy
  4. World
  5. Nuclear
  6. Society/Culture
  7. Space/Science
  8. Sports
  9. Tourism
  10. Other Media
  11. Videos
  12. Photos
  13. Cartoons
  14. Interview
    • فارسی
    • عربی
    • Türkçe
    • עברית
    • Pусский
  • RSS
  • Telegram
  • Instagram
  • Twitter
  • Facebook
  • All Stories
  • Politics
  • Economy
  • World
  • Nuclear
  • Society/Culture
  • Space/Science
  • Sports
  • Tourism
  • Other Media
  • Videos
  • Photos
  • Cartoons
  • Interview

Japan Receives Requests for Avigan from about 30 Countries Hit by Coronavirus

  • April, 04, 2020 - 12:26
  • Other Media news
Japan Receives Requests for Avigan from about 30 Countries Hit by Coronavirus

TEHRAN (Tasnim) – The Japanese government plans to provide nations hit by the coronavirus pandemic with the anti-flu drug Avigan developed by a Japanese chemical firm.

Other Media

Clinical trials of Avigan are now underway in Japan to examine the effectiveness and safety of the drug for potential use in treating symptoms caused by the new coronavirus.

Chief Cabinet Secretary Yoshihide Suga told reporters on Friday that the government has so far received requests for the drug from about 30 countries.

Suga said the government plans to expand clinical trials of Avigan while having discussions with the countries that placed the requests, NHK reported.

He added that it will provide each of those nations with the amount of the drug they need, free of charge.

The German government reportedly plans to procure millions of packs of Avigan to treat coronavirus patients with severe illness.

Researchers in China say that Avigan proved effective in clinical trials with people infected with the coronavirus.

 
R7839/P42410
Related topics
  • coronavirus
Read more
US Regulator Gives Anti-Malaria Drugs Emergency Approval to Treat Coronavirus
tasnim
tasnim
tasnim
  • About
  • Contact Us
  • Most Visited
  • Archive
Follow Us:
  • RSS
  • Telegram
  • Instagram
  • Twitter
  • Facebook

All Content by Tasnim News Agency is licensed under a Creative Commons Attribution 4.0 International License.